Loading...
  • allogeneic
  • Allogeneic BMT recipients deficient in IL-17A also develop accelerated GVHD, suggesting MAIT cells likely regulate GVHD, at least in part, by the generation of this cytokine. (jci.org)
  • While allogeneic stem cell transplants have the potential to transform people's lives, the onset of acute GVHD can significantly impact their prognosis. (onclive.com)
  • PTCy was effective in preventing both acute and chronic GVHD given its capacity to preferentially eliminate allo-reactive T cells and preserve regulatory T cells, both of which impact allogeneic immune reactions. (bioportfolio.com)
  • However, BM is not the preferred source of stem cells after RIC allo-SCT, and the potential efficacy of PTCy on preventing GVHD when using PBSCs (which is the most frequently used source of allogeneic cells worldwide) is debated. (bioportfolio.com)
  • He is best known for his research on chronic GVHD, the most common late effect in cancer survivors who underwent allogeneic stem cell transplantations as a form of treatment. (wikipedia.org)
  • The United States Embassy in Zagreb, Croatia, granted Pavletic a United States Government stipend to spend six weeks at the University Hospital Centre Zagreb, Croatia, in 2013, to assist in the establishment of a multidisciplinary center for the treatment of chronic GVHD resulting from allogeneic stem cell transplantations. (wikipedia.org)
  • Some of these antigens are ubiquitiouly expressed in nucleated male cells, and the presence of these antigens has been associated with a greater risk of developing GVHD allogeneic stem cell transplantation for a HLA matched gene when there's a male recipient and female donor. (wikipedia.org)
  • Transfer of cells are made between allogeneic hosts but the new host is irradiated for preventing rejection or GVHD. (wikipedia.org)
  • relapse-free survival
  • The protocol will use a novel endpoint for benchmarking interventions based on a composite primary endpoint of GVHD-free, relapse-free survival which measures freedom from ongoing morbidity and represents an ideal outcome measure after allo-SCT. (bioportfolio.com)
  • phase
  • For example, Pluristem is using forward-looking statements when its discusses its proposed Phase I/II trial studying Pluristem's PLX-PAD cell therapy, the potential for PLX-PAD and Pluristem's hopes to address GvHD to help patients lead full lives after undergoing a transplant. (globenewswire.com)
  • If you are still on this study at the end of the induction phase, meaning you have had no serious side effects and your GVHD has not progressed, ou wil continue to the next phase of this study. (clinicaltrials.gov)
  • Preliminary results of a phase III trial for GvHD were released in Sept 2009. (wikipedia.org)
  • onset
  • Clinical data to be collected and reported include the onset of GVHD, grade, organ involved, and treatments used. (clinicaltrials.gov)
  • Researchers
  • Researchers have never tried to target the CD30 molecule for the treatment of GVHD, but results from other research studies show that it could help slow the growth of your disease. (clinicaltrials.gov)
  • Moffitt Cancer Center researchers are trying to identify new drug targets to reduce the risk of GVHD. (medicalxpress.com)
  • In collaboration with researchers from the Medical University of South Carolina, the Moffitt research team wanted to confirm the link and assess if blocking JAK2 could reduce the occurrence of GVHD. (medicalxpress.com)
  • cohort
  • This goal will be accomplished by assembling a large modern cohort of people with chronic GVHD at four large core transplant centers. (clinicaltrials.gov)
  • In a 64-patient cohort with serum samples three weeks after tranplant, Tim-3 was the strongest univariate risk factor examined to predict mid-gut GVHD development. (fredhutch.org)
  • cells
  • GVHD results when immune system cells from a donor cause inflammation in the patient receiving them. (cityofhope.org)
  • However, it remains unclear whether Th1 or Th17 CD4+ T cells can initiate acute gut GVHD. (jci.org)
  • In this issue of the JCI, Ullrich and colleagues identified a subset of CD4+ T cells that express high levels of IL-7Rα and granulocyte-macrophage CSF (IL-7RαhiGM-CSF+) cells that are involved in the induction of acute gut GVHD in murine models. (jci.org)
  • Studies show that between 2 and 6 out of every 10 patients transplanted with donor cells will develop some level of GVHD after transplant. (aamds.org)
  • They also showed that donor cells missing the JAK2 gene induced GVHD less than normal donor cells, and the genetically modified cells were still able to target tumor cells for destruction. (medicalxpress.com)
  • These observations suggest drugs that target JAK2 may prevent GVHD and still allow the donor cells to target cancer cells. (medicalxpress.com)
  • By immunohistochemistry staining, IL-21 protein-producing cells were present in all gastrointestinal tract samples and 54% of skin samples obtained from GVHD patients but not GVHD-free controls. (bloodjournal.org)
  • 6 , 7 Like Th1 and Th2 cells, the role of Th17 cells in GVHD is controversial. (bloodjournal.org)
  • Whereas cotransfer of highly purified ex vivo polarized Th17 cells with naive T cells results in a more aggressive disease that is dependent on IL-17, 8 CD4 + T cells from IL-17 −/− or RORγt (Th17-deficient) donors attenuate, exacerbate, or had no effect on GVHD, depending on the model and knockout strain. (bloodjournal.org)
  • Therefore, these T cells are auto-reactive and cause the GVHD phenotype. (wikipedia.org)
  • Immunosuppressive
  • and (2) defining significant variables for a chronic GVHD activity index that predicts short-term (provider perception of change, patient perception of change, and changes in immunosuppressive medications) and longer-term outcomes (overall survival, time to discontinuation of systemic immunosuppressive therapy, and functional impairments). (clinicaltrials.gov)
  • Jakafi
  • We are proud of the impact Jakafi has had on patients' lives to-date and are dedicated to advancing our ongoing research in JAK inhibition to serve more GVHD patients in the future. (onclive.com)
  • protein
  • Recent research studies have found increased levels of protein called CD30 in people with acute GVHD. (clinicaltrials.gov)
  • Their new study, published last week in the Proceedings of the National Academy of Sciences , shows a drug that targets the protein JAK2 may reduce the risk of GVHD. (medicalxpress.com)
  • The protein JAK2 is believed to be involved in the development of GVHD. (medicalxpress.com)